Demis Hassabis, a Nobel laureate for his AI research and the CEO of Google DeepMind, said on Sunday that he hopes that AI ...

In a perspective, Northwestern Engineering’s Chad Mirkin and Milan Mrksich argue that structural precision drives therapeutic ...

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

Press Release Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, today ...

Hassabis also spoke to Reid Hoffman, co-founder of LinkedIn, about the scale and speed at which AI is transforming science. Using DeepMind’s AlphaFold technology, researchers managed to predict the ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug ...

Demis Hassabis, the co-founder and CEO of Google DeepMind, has made an audacious claim that artificial intelligence could ...

Exscientia, headquartered in Oxford, UK, has been a pioneer in integrating AI into small-molecule drug design. The company’s platform, Centaur Chemist, combines human expertise with AI to generate ...